H.C. Wainwright Maintained Buy on Alpha Tau Medical Ltd. (DRTS) Feb 2026
H.C. Wainwright maintained a Buy rating on Alpha Tau Medical Ltd. (DRTS) on February 24, 2026. This DRTS analyst rating included a price target increase to $12 from $9, a clear sign the firm sees stronger near-term value. The market reacted with a modest pullback of -1.4% (-$0.11) on the update. We cover the rating details, price target, and what this action means for investors assessing DRTS.
DRTS analyst rating: H.C. Wainwright maintained Buy on Feb 24, 2026
H.C. Wainwright published a note on February 24, 2026 at 10:29 AM, maintaining its Buy rating while raising the Alpha Tau price target to $12 from $9. The firm signaled confidence in the company’s clinical progress and commercial pathway as the rationale for the change. The original report is summarized by TheFly.
DRTS analyst rating: historical coverage and the single change
This is the only recent rating change recorded on February 24, 2026 for DRTS, and it comes solely from H.C. Wainwright. The firm moved the price target from $9 to $12, but kept the Buy rating unchanged. Historically, analyst coverage of Alpha Tau Medical Ltd. has been limited, and this action keeps H.C. Wainwright as a primary voice on the stock.
DRTS analyst rating: what the maintained Buy means for investors
A maintained Buy indicates the analyst still prefers Alpha Tau versus peers, rather than signaling a new positive turn. Investors should read this as continued conviction from H.C. Wainwright, driven by expected clinical and commercial milestones. The maintained stance reduces short-term surprise risk but does not guarantee stock gains.
DRTS analyst rating: stock reaction and market context
The market responded by moving DRTS down -1.4% (-$0.11) on the update, a modest decline despite the higher price target. Alpha Tau Medical Ltd. had a market cap of $630,528,360 around the announcement. Sector volatility and company-specific catalysts often drive short-term moves, so price action can diverge from analyst views.
DRTS analyst rating: price target implications and valuation notes
H.C. Wainwright’s new $12 price target sets a concrete benchmark for expected value. For investors, the target frames potential upside and helps compare Alpha Tau to peers and indices. Price targets are analyst estimates, not guarantees, and should be weighed with financials, pipeline milestones, and risk factors.
DRTS analyst rating: Meyka AI view and proprietary grade
Meyka AI rates DRTS with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. As an AI-powered market analysis platform, we track real-time analyst moves, but grades are not guarantees and do not replace personalized financial advice. For the H.C. Wainwright note, see our DRTS page for tracked updates and history Meyka DRTS page.
Final Thoughts
H.C. Wainwright’s action on February 24, 2026 kept a Buy rating on Alpha Tau Medical Ltd. while raising the price target to $12 from $9. That single, notable DRTS analyst rating preserved the firm’s positive view while assigning a higher valuation benchmark. Investors should view the maintained Buy as continued analyst confidence, not a new upgrade. The market’s -1.4% (-$-0.11) reaction shows short-term sentiment can differ from analyst expectations. Meyka AI rates DRTS with a grade of B, reflecting relative strength against benchmarks and analyst sentiment. We recommend investors weigh the H.C. Wainwright note with company fundamentals, pipeline timelines, and risk tolerance before making new positions. Our coverage tracks changes in real time to help contextualize analyst moves for portfolio decisions.
FAQs
What exactly changed in the DRTS analyst rating on Feb 24, 2026?
H.C. Wainwright maintained a Buy rating and raised the Alpha Tau price target to $12 from $9 on February 24, 2026. The firm cited clinical and commercial progress as reasons for the price target increase.
How should investors interpret a maintained Buy in the DRTS analyst rating?
A maintained Buy means the analyst still prefers Alpha Tau versus peers. It signals continued conviction but not a fresh upgrade. Investors should combine this view with company fundamentals and risk tolerance.
Did DRTS stock move after the analyst update and what is the market cap?
Yes. The stock moved -1.4% (-$0.11) on the announcement. Alpha Tau Medical Ltd. had a market cap of $630,528,360 near the update, per the reporting.
Where can I read the H.C. Wainwright note on the DRTS analyst rating?
The H.C. Wainwright note summarized the rating and price target change. A report summary is available on TheFly.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.